Ana Paula Neves Burian
Overview
Explore the profile of Ana Paula Neves Burian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sartori N, Machado K, Miyamoto S, Pretti F, Gouveia M, de Oliveira Y, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006674
Objective: To evaluate the humoral response to and impact of SARS-CoV-2 vaccination in patients with systemic lupus erythematosus in a multicenter cohort design. Methods: Data for this analysis were obtained...
2.
Machado K, Burian A, Martins-Filho O, Mill J, Ferreira L, Tapia K, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772029
Background/objectives: The effectiveness of COVID-19 vaccine in patients with immune-mediated inflammatory diseases (IMID) depends on the underlying disease, immunosuppression degree and the vaccine regimens. We evaluate the safety and immunogenicity...
3.
Calderaro D, Valim V, Ferreira G, Machado K, Ribeiro P, Ribeiro S, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340061
Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD...
4.
Cruz V, Guimaraes C, Rego J, Machado K, Miyamoto S, Burian A, et al.
Adv Rheumatol
. 2024 Aug;
64(1):58.
PMID: 39135131
Background: Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. Patients with rheumatoid arthritis (RA) are at a high risk of...
5.
Casagrande T, da Costa-Rocha I, de Oliveira Gavi M, Miyamoto S, Costa Martins P, Serrano E, et al.
Vaccine
. 2022 Jun;
40(32):4580-4593.
PMID: 35728990
Yellow fever (YF) vaccination is known to induce a suboptimal response in patients with autoimmune diseases (AIDs). To date, few studies have focused on the performance of 17DD-YF vaccination in...
6.
da Costa-Rocha I, Machado K, Campi-Azevedo A, Teixeira-Carvalho A, Peruhype-Magalhaes V, de Lima S, et al.
Sci Rep
. 2021 May;
11(1):10431.
PMID: 34001945
The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune diseases (AID) upon planned primary 17DD-YF vaccination. For this...
7.
Valim V, Machado K, Miyamoto S, Pinto A, Rocha P, Serrano E, et al.
Front Immunol
. 2020 Aug;
11:1382.
PMID: 32765496
Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies...